National Bank of Canada’s Adaptive Biotechnologies ADPT Stock Holding History

National Bank of Canada’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-703	Closed	-$2.51K	–	2735
2024 Q2	$2.51K	Hold	703	–	–	﹤0.01%	2388
2024 Q1	$2.46K	Buy	703 +500	+246%	+$1.94K	﹤0.01%	2423
2023 Q4	$969	Hold	203	–	–	﹤0.01%	2541
2023 Q3	$1.04K	Hold	203	–	–	﹤0.01%	2583
2023 Q2	$1.36K	Hold	203	–	–	﹤0.01%	2520
2023 Q1	$1.79K	Hold	203	–	–	﹤0.01%	2459
2022 Q4	$1.54K	Hold	203	–	–	﹤0.01%	2531
2022 Q3	$1K	Hold	203	–	–	﹤0.01%	2564
2022 Q2	$2K	Sell	203 -113,000	-100%	-$994K	﹤0.01%	2579
2022 Q1	$1.57M	Buy	113,203 +113,000	+55,665%	+$1.78M	﹤0.01%	952
2021 Q4	$6K	Buy	+203	New	+$6.22K	﹤0.01%	2484

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

National Bank of Canada's ADPT Position: Q3 2024 in Review

National Bank of Canada sold out of Adaptive Biotechnologies (ADPT) in Q3 2024, closing a stake of 703 shares — an estimated $2.51K sold.

National Bank of Canada first reported a position in ADPT in Q4 2021 and held it in 11 quarters. The position peaked at $1.57M in Q1 2022. 187 funds tracked by Wall St. Rank hold ADPT as of Q3 2024.

National Bank of Canada reported no remaining Adaptive Biotechnologies position as of Q3 2024 after selling out during the quarter.
National Bank of Canada sold 703 Adaptive Biotechnologies shares in Q3 2024, an estimated $2.51K.
National Bank of Canada first reported a position in Adaptive Biotechnologies in Q4 2021 and held it in 11 quarters.
National Bank of Canada's Adaptive Biotechnologies position peaked at $1.57M in Q1 2022.
187 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2024.

Based on National Bank of Canada's 13F filing for Q3 2024, filed 12 Nov 2024.